Mid Dose for Age-related Macular Degeneration

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Age-related Macular Degeneration+1 MoreVOY-101 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Eligible Conditions
  • Age-related Macular Degeneration
  • Age-Related Macular Degeneration (AMD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Through 24 months

Through 24 months
Safety Endpoints

Trial Safety

Safety Progress

1 of 3

Trial Design

7 Treatment Groups

Randomized Cohort--MTD
1 of 7
Randomized Cohort--MTD-1
1 of 7
Mid Dose
1 of 7
Low Dose
1 of 7
High Dose
1 of 7
Randomized Cohort
1 of 7
Randomized Cohort--Sham
1 of 7

Active Control

Experimental Treatment

Non-Treatment Group

45 Total Participants · 7 Treatment Groups

Primary Treatment: Mid Dose · Has Placebo Group · Phase 1 & 2

Mid Dose
Biological
Experimental Group · 1 Intervention: VOY-101 · Intervention Types: Biological
Low Dose
Biological
Experimental Group · 1 Intervention: VOY-101 · Intervention Types: Biological
High Dose
Biological
Experimental Group · 1 Intervention: VOY-101 · Intervention Types: Biological
Randomized Cohort
Biological
Experimental Group · 1 Intervention: VOY-101 · Intervention Types: Biological
Randomized Cohort--MTD
Biological
ActiveComparator Group · 1 Intervention: VOY-101 · Intervention Types: Biological
Randomized Cohort--MTD-1
Biological
ActiveComparator Group · 1 Intervention: VOY-101 · Intervention Types: Biological
Randomized Cohort--Sham
Biological
ShamComparator Group · 1 Intervention: VOY-101 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through 24 months

Who is running the clinical trial?

Perceive Biotherapeutics, Inc.Lead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 50 years of age.
You have GA secondary to AMD in the absence of MNV and in the absence of history of MNV.
You are willing and able to return for scheduled treatment and follow-up examinations.
You have no signs of non-exudative MNV.